An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29617394.
- Also identified by DOI 10.1371/journal.pone.0194830 and PMC identifier 5884525.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The standard method to quantify the hemagglutinin content of influenza virus vaccines is the single radial immunodiffusion assay. This assay primarily relies on polyclonal antibodies against the head domain of the influenza virus hemagglutinin, which is the main target antigen of influenza virus vaccines. Novel influenza virus vaccine candidates that redirect the immune response towards the evolutionary more conserved hemagglutinin stalk, including chimeric hemagglutinin and headless hemagglutinin constructs, are highly dependent on the structural integrity of the protein to present conformational epitopes for neutralizing antibodies. In this study, we describe a novel enzyme-linked immunosorbent assay that allows quantifying the amount of hemagglutinin with correctly folded stalk domains and which could be further developed into a potency assay for stalk-based influenza virus vaccines.
Medical subject headings
- Enzyme-Linked Immunosorbent Assay
- Hemagglutinin Glycoproteins, Influenza Virus
- Influenza Vaccines